ReviewBlood research2026
Interest of luspatercept in treatment of anemia in lower-risk of myelodysplastic syndrome anemia: a single center study of 26 patients.
Review in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyelodysplastic syndromes (MDS) are heterogeneous clonal hematological disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenias. Luspatercept, an erythroid maturation agent, represents a novel therapeutic option for the management of anemia associated with low-risk MDS, particularly in patients with ring sideroblasts and/or SF3B1 mutations.
methodsWe retrospectively studied 26 adults with low- or intermediate-risk MDS who were treated with luspatercept from 2021 to 2024 at the Nice University Hospital. Data were collected from ORBIS and CLINICOM and analyzed using Microsoft Excel. Treatment was initiated at 1 mg/kg, depending on the patient.
resultsThe median age was 74 years, and 38.5% of patients had the SF3B1 mutation. Erythroid response was achieved in 53.8% of patients according to International Working Group (IWG) 2023. Treatment was generally well tolerated, with fatigue being the most common side effect (26.9%).
conclusionLuspatercept appears to be effective in improving red blood cell production and reducing transfusion requirements in low-risk patients with MDS, with a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.